diabetes mellitus type 2/triglyceride

Lyen an sove nan clipboard la

Chwazi kalite sòt

13 rezilta yo

Composition and method of Lactobacillus reuteri GMNL-89 in treating type 2 diabetes

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to new use of Lactobacillus isolates, in particular, to the technical field of treatments for type II diabetes. 2. Description of the Prior Art Diabetes Mellitus is a metabolism disease of many pathogens. It is a

Triglyceride reducing agent

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to triglyceride reducing agents for use in the human body, and, more particularly, a flavour compound for prevention and treatment of hyperlipidemia (hypertriglyceridemia). 2. Description of Related Art The

Compositions and methods for the treatment of metabolic syndrome

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1853/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/051596 filed on 28 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into

Carboxyalkylethers, formulations, and treatment of vascular diseases

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION This invention relates to compounds which are dialkyl ethers having terminal carboxy or tetrazole groups. The compounds are useful for lowering certain plasma lipids in animals, including Lp(a), triglycerides, VLDL-cholesterol, and LDL-cholesterol, and elevating others such as

Carboxyalkylethers, formulations, and treatment of vascular diseases

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Carboxyalkylethers, formulations, and treatment of vascular diseases

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION Vascular diseases such as coronary heart disease, stroke, restenosis, and peripheral vascular disease, remain the leading cause of death and disability throughout the world. About 1.5 million people die each year in the US alone from myocardial infarction resulting from

Carboxyalkylethers, formulations, and treatment of vascular diseases

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Composition containing cinchonine as an active ingredient for preventing and treating obesity, dyslipidemia, fatty liver, or insulin resistance syndrome

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2010/008944, filed Dec. 14, 2010, which claims benefit of Korean Patent Application No. 10-2010-0004901, filed Jan. 19, 2010. FIELD OF THE

Trans-clomiphene metabolites and uses thereof

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention relates to metabolites of trans-clomiphene in substantially pure form, pharmaceutical compositions comprising same and methods for treating various hormone-dependent disorders. BACKGROUND Clomiphene is a selective estrogen receptor modulator related to

Sulfonamides as GPR40- and GPR120-agonists

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BRIEF DESCRIPTION OF THE INVENTION The present invention relates to compounds that acts as G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40) agonists, pharmaceutical compositions containing them and their use in the treatment of diseases or disorders modulated by said GPRs such as diabetes

Method for treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredient

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2009/007905, filed Dec. 29, 2009, which claims benefit of Korean Patent Application 10-2009-0022937, filed Mar. 18, 2009. TECHNICAL FIELD The

Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK Not Applicable BACKGROUND OF THE INVENTION In 2003, the International Diabetes Federation estimated that there were 194 million people worldwide with diabetes. Of these, some 16 million

Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Oxidative stress and inflammation are implicated in the pathogenesis of metabolic diseases, diabetes, obesity, dyslipidemia and their associated cardiovascular complications. For example, oxidative stress is a common pathogenic factor leading to insulin resistance, beta-cell dysfunction,

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye